The Company has a successful history in developing pharmaceutical products, including Crinone® 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world.
We are currently developing several product candidates using our segmented intravaginal ring (IVR) technology. The most advanced of these is JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women.
We are leveraging the in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services to advance an internal product pipeline, while also providing valuable intellectual property-related consultative services to our pharmaceutical industry customers.
Juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to advance a proprietary pipeline for long term value creation.
Closing share price
|FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$29.2 m||$32.5 m||$37.6 m||$54.6 m|
Revenue growth, %
Cost of goods sold
|$13.3 m||$17.7 m||$21.4 m||$24.3 m|
Operating expense total
|$10.1 m||$11 m||$18.7 m||$25 m|
|$5.9 m||$3.8 m||($2.5 m)||$5.3 m|
Income tax expense
|$22.6 k||$988 k||$5 k||$91 k|
Pre tax profit
|$6.7 m||$4.4 m||($2.1 m)||$6 m|
|$6.7 m||$3.4 m||($2.1 m)||$6 m|